ProCE Banner Activity

SELECT-CHOICE: Upadacitinib vs Abatacept in Patients With Rheumatoid Arthritis With Inadequate Response or Intolerance to bDMARDs

Slideset Download
Conference Coverage
At 12 weeks, change in DAS28-CRP with upadacitinib was noninferior to (primary endpoint) and also superior to (secondary endpoint) abatacept. Upadacitinib was also associated with superior rate of clinical remission (DAS28-CRP < 2.6).

Released: August 17, 2020

Expiration: August 16, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AbbVie Inc.

Gilead Sciences, Inc.